Merck & Co Analyst Price Targets

Wall Street analyst price targets and consensus rating for Merck & Co (MRK).

Price Target Range — 10 Quarters

Analyst Consensus — 24 Analysts

15Buy

9Hold

Consensus RatingBuy# Analysts24Avg. Consensus PT$145Upside to Avg. PT-0.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$125→$145
Oct 12, 2026	RBC Capital	Trung Huynh	PT Cut	Sector Perform	$150→$145
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$120→$145
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$179→$177
Oct 5, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$150→$165
Sep 29, 2026	Scotiabank	Louise Chen	PT Raise	Sector Outperform	$155→$180
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$150→$172
Sep 9, 2026	Leerink Partners	Daina Graybosch	PT Raise	Outperform	$127→$161
Sep 8, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$146→$170
Sep 4, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$150→$170
Aug 25, 2026	Wolfe Research	Alexandria Hammond	PT Raise	Outperform	$155→$180
Aug 25, 2026	Argus Research	Jasper Hellweg	PT Raise	Buy	$145→$170
Aug 21, 2026	Goldman Sachs	Terence Flynn	PT Raise	Buy	$140→$160
Aug 20, 2026	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$142→$170
Aug 20, 2026	UBS	Michael Yee	PT Raise	Buy	$145→$175
Aug 20, 2026	RBC Capital	Trung Huynh	Downgrade	Outperform→Sector Perform	$142→$150
Aug 20, 2026	Morgan Stanley	Terence Flynn	Upgrade	Equal-Weight→Overweight	$116→$179
Aug 12, 2026	Daiwa Capital	Narumi Nakagiri	Upgrade	Neutral→Outperform	$120→$143
Aug 11, 2026	Argus Research	Jasper Hellweg	PT Raise	Buy	$130→$145
Aug 5, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$145→$146

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Merck & Co, Raises Price Target to $145

Citigroup analyst Geoff Meacham maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $125 to $145.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $145

RBC Capital analyst Trung Huynh maintains Merck & Co (NYSE:MRK) with a Sector Perform and lowers the price target from $150 to $145.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $145

Cantor Fitzgerald analyst Carter Gould maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $120 to $145.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $177

Morgan Stanley analyst Terence Flynn maintains Merck & Co (NYSE:MRK) with a Overweight and lowers the price target from $179 to $177.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $165

JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $165.

Benzinga Newsdesk

PRO
Scotiabank Maintains Sector Outperform on Merck & Co, Raises Price Target to $180

Scotiabank analyst Louise Chen maintains Merck & Co (NYSE:MRK) with a Sector Outperform and raises the price target from $155 to $180.

Benzinga Newsdesk

Merck & Co Inc

Merck & Co Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Merck & Co, Raises Price Target to $145

PRO
RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $145

PRO
Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $145

PRO
Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $177

PRO
JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $165

PRO
Scotiabank Maintains Sector Outperform on Merck & Co, Raises Price Target to $180

People Also Watch

People Also Watch

Merck & Co Inc

Merck & Co Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Maintains Neutral on Merck & Co, Raises Price Target to $145

PRORBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $145

PROCantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $145

PROMorgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $177

PROJP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $165

PROScotiabank Maintains Sector Outperform on Merck & Co, Raises Price Target to $180

People Also Watch

People Also Watch

PRO
Citigroup Maintains Neutral on Merck & Co, Raises Price Target to $145

PRO
RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $145

PRO
Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $145

PRO
Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $177

PRO
JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $165

PRO
Scotiabank Maintains Sector Outperform on Merck & Co, Raises Price Target to $180